Welcome to our dedicated page for Senzime AB (publ) news (Ticker: $snzzf), a resource for investors and traders seeking the latest updates and insights on Senzime AB (publ) stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Senzime AB (publ)'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Senzime AB (publ)'s position in the market.
Senzime (STO:SEZI)(OTCQX:SNZZF), a leading provider of perioperative precision-based patient monitoring solutions, has appointed Dr. Wolfgang Reim as the new senior advisor to its Board of Directors. Dr. Reim brings extensive experience from his previous roles, including CEO of Dräger Medical and the Ultrasound Division at Siemens Healthcare. His background includes serving on the boards of Elekta AB, GN Store Nord, Carl Zeiss, and Ondal Medical Systems. Senzime CEO Philip Siberg expressed high expectations for Dr. Reim's expertise in global commercialization and medical technologies, which are anticipated to support the company's rapid growth objectives.
The annual general meeting of Senzime AB was held on May 16, 2024, in Uppsala. Key resolutions include the adoption of the income statement and balance sheet for 2023, with no dividends to be paid. Discharge from liability was granted to board members and the managing director. Remuneration was set, with the chairman receiving SEK 450,000 and the auditor paid per approved invoice. The board will consist of six directors, and PricewaterhouseCoopers was re-elected as auditor. An employee stock option program for 2024/2028 was introduced, and the board was authorized to issue new shares to facilitate the acquisition of Respiratory Motion. Additionally, the board was authorized to increase the company's share capital by up to 20% until the next annual general meeting.
Senzime AB reported a 66% increase in net sales for January - March 2024, with sales of instruments up by 41% and disposables up by 89%. The gross margin decreased to 64.3%, EBITDA improved, but profit after financial items showed a loss. Cash and cash equivalents increased to TSEK 116,856. The company secured a significant deal in the US and saw growth in Japan and South Korea. CEO Philip Siberg highlighted the strong sales growth and emphasized the focus on building a market-leading position. The future outlook remains optimistic with high demand in the market.
Senzime invites investors, analysts, and media to a webcast presentation of the first quarter report for 2024 on May 7th. The presentation will be held by Philip Siberg, CEO, with a Q&A session moderated by an analyst from Carnegie Investment Bank. The event will be held in English and can be accessed via webcast.
